

L Number	Hits	Search Text	DB	Time stamp
-	1524	angiogenic ADJ factor	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 10:41
-	23010	chimeric	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 10:41
-	145232	chimeric or fusion	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 10:41
-	9	(angiogenic ADJ factor) same chimeric	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 10:46
-	23013	vegf adj fusion or chimeric	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 10:47
-	17	vegf adj (fusion or chimeric)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 10:48
-	10	fgf adj (fusion or chimeric)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 10:48
-	46	vegf\$ adj (fusion or chimeric)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 10:59
-	0	vaegf-A and (vegf\$ adj (fusion or chimeric))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 10:59
-	0	vaegf-A121 and (vegf\$ adj (fusion or chimeric))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:00
-	0	vaegf-A or VEGF-A121 OR VEGF-A145 OR VEGF-A165 OR VEGF-A189 OR VEGF-A206	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:01
-	174	vegf-A or VEGF-A121 OR VEGF-A145 OR VEGF-A165 OR VEGF-A189 OR VEGF-A206	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:03
-	152	(vegf-A or VEGF-A121 OR VEGF-A145 OR VEGF-A165 OR VEGF-A189 OR VEGF-A206) AND (chimeric or fusion)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:02
-	0	(vegf-A or VEGF-A121 OR VEGF-A145 OR VEGF-A165 OR VEGF-A189 OR VEGF-A206) NEAR (chimeric or fusion)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:02
-	9	(vegf-A or VEGF-A121 OR VEGF-A145 OR VEGF-A165 OR VEGF-A189 OR VEGF-A206) SAME (chimeric or fusion)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:03

-	218	vegf-B or VEGF-B167 OR VEGF-B186	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:22
-	205	vegf-d	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:03
-	134	vegf-E	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:03
-	1551	(ACIDIC ADJ FIBROBLAST ADJ GROWTH ADJ FACTOR) OR AFgf	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:04
-	2918	(BASIC ADJ FIBROBLAST ADJ GROWTH ADJ FACTOR) ORBFgf	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:05
-	540007	ANGIOPOIETIN-1 OF ang1	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:05
-	13	vegf-d SAME (chimeric or fusion)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:05
-	5	vegf-E SAME (chimeric or fusion)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:06
-	50	((ACIDIC ADJ FIBROBLAST ADJ GROWTH ADJ FACTOR) OR AFgf) SAME (chimeric or fusion)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:06
-	70	((BASIC ADJ FIBROBLAST ADJ GROWTH ADJ FACTOR) ORBFgf) SAME (chimeric or fusion)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:06
-	13	(ANGIOPOIETIN-1 OF ang1) SAME (chimeric or fusion)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:06
-	12	(vegf-B or VEGF-B167 OR VEGF-B186) SAME (chimeric or fusion)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:07
-	6	VEGF-B167	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:23

were significantly less necrotic, suggesting that necrosis in these tumors is the result of insufficient angiogenesis.

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:777911 CAPLUS

DOCUMENT NUMBER: 128:71142

TITLE: Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate

AUTHOR(S): Olson, Timothy A.; Mohanraj, D.; Roy, Sabita; Ramakrishnan, S.

CORPORATE SOURCE: Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA

SOURCE: International Journal of Cancer (1997), 73(6), 865-870

CODEN: IJCNW; ISSN: 0020-7136

PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Tumor-derived vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) plays an important role in neovascularization and the development of tumor stroma. Furthermore, VEGF receptors are over-expressed in the endothelial cells of tumor vasculature and almost non-detectable in the vascular endothelium of adjoining normal tissues. The differential expression of receptor offers a selective advantage for targeting cytotoxic toxin polypeptides. We have prep'd. a vascular targeting reagent by chem. linking recombinant VEGF to a truncated form of diphtheria toxin. The VEGF-toxin conjugate was selectively toxic to endothelial cell lines and inhibited exptl. neovascularization of the chick chorioallantoic membrane. In the present study, we examd. the effects of VEGF-toxin conjugate on solid tumor growth. Athymic nude mice with established s.c. tumors were treated with daily i.p. injections of the VEGF-toxin conjugate or free toxin. When compared with control animals treated with the toxin polypeptide alone, the conjugate-treated animals displayed a significant inhibition of tumor growth. Histol. anal. of tumors from conjugate-treated animals revealed hemorrhagic necrosis consistent with a vascular-mediated injury. In contrast, highly vascularized normal tissues from conjugate-treated animals demonstrated no evidence of hemorrhage or tissue injury. The conjugate was well tolerated without apparent toxicities. Our results illustrate the anti-tumor activity of a VEGF-toxin conjugate selectively targeting the tumor neovasculature.

L9 ANSWER 3 OF 3 PCTFULL COPYRIGHT 2003 Univentio

**** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

**** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

=> d his

(FILE 'HOME' ENTERED AT 16:59:28 ON 08 JAN 2003)

FILE 'MEDLINE' ENTERED AT 16:59:40 ON 08 JAN 2003

L1 6036 S VEGF?

L2 102848 S FUSION

L3 59 S L1 (S) L2

L4 220976 S TARGET?

L5 126030 S ENDOTHELI?

L6 14 S L1 (S) L2 (S) L4 (S) L5

FILE 'BIOSIS, EMBASE, SCISEARCH, CAPLUS, PCTFULL' ENTERED AT 17:05:43 ON 08 JAN 2003

L7 86 S L6

L8 59 DUP REM L7 (27 DUPLICATES REMOVED)

L9 3 S L8 NOT PY>1998

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
------------------	---------------

FULL ESTIMATED COST

17.86	24.81
-------	-------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
------------------	---------------

CA SUBSCRIBER PRICE

-0.65	-0.65
-------	-------

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 17:09:24 ON 08 JAN 2003

transgeniques exprimant ces protéines et des analogues fonctionnellement équivalents de ces protéines. L'invention concerne enfin des méthodes permettant d'induire la différenciation de motoneurones somatiques et de traiter des maladies liées à la carence en motoneurones fonctionnant normalement, des maladies neurodégénératives, des troubles neurologiques et des maladies neuromusculaires.

L17 ANSWER 5 OF 5 MEDLINE DUPLICATE 2
ACCESSION NUMBER: 95403738 MEDLINE
DOCUMENT NUMBER: 95403738 PubMed ID: 7673487
TITLE: Transplanted human neurons derived from a teratocarcinoma cell line (NTera-2) mature, integrate, and survive for over 1 year in the nude mouse brain.
AUTHOR: Kleppner S R; Robinson K A; Trojanowski J Q; Lee V M
CORPORATE SOURCE: Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical School, Philadelphia 19104, USA.
SOURCE: JOURNAL OF COMPARATIVE NEUROLOGY, (1995 Jul 10) 357 (4) 618-32.
PUB. COUNTRY: Journal code: 0406041. ISSN: 0021-9967.
DOCUMENT TYPE: United States
LANGUAGE: Journal; Article; (JOURNAL ARTICLE)
FILE SEGMENT: English
ENTRY MONTH: Priority Journals
ENTRY DATE: 199510
Entered STN: 19951026
Last Updated on STN: 19970203
Entered Medline: 19951019
AB Retinoic acid (RA) induces a human teratocarcinoma cell line (NTera-2 or NT2) to give rise exclusively to ***post*** - ***mitotic*** ***neuron*** -like (NT2N) cells, but NT2N cells never acquire a fully mature neuronal phenotype in vitro. To determine whether NT2N cells can mature into adult neuron-like cells in vivo, purified NT2N cells were grafted into different regions of the central nervous system (CNS) of adult and neonatal athymic mice, and the grafts were examined immunohistochemically by light, confocal, and electron microscopy using antibodies to a panel of developmentally regulated neuronal polypeptides. NT2N grafts were distinguished from endogenous mouse neurons with antibodies that recognize human or murine specific epitopes in selected neuronal polypeptides. Viable NT2N cells were identified in > 89% of graft recipients (N = 90), and some grafts survived 14 months. Within 3 weeks of ***implantation***, grafted NT2N cells re-extended their processes, and the location of the grafts (e.g., septum versus neocortex) appeared to determine the extent to which processes were elaborated. Within the early post-transplantation period, grafted NT2N cells expressed the same neuronal polypeptides as their in vitro counterparts. However, between 6 weeks and 4-6 months post- ***implantation***, the grafted NT2N cells progressively acquired the molecular phenotype of fully mature in vivo neurons as evidenced by dramatically increased expression of the most highly phosphorylated isoforms of the heavy neurofilament subunit, and the de novo expression of adult CNS tau. Notably, the time course for the extension of processes and the expression of neuronal polypeptides by NT2N grafts was similar in neonatal and adult mice. Although grafted NT2N cells formed synapse-like structures and elaborated dendrites and axons, these axons remained unmyelinated. Finally, none of the transplanted NT2N cells reverted to a neoplastic state. These studies demonstrate that pure populations of grafted human NT2N cells acquire a fully mature neuronal phenotype in vivo, and that these cells integrate and survive for > 1 year post- ***implantation*** in the mouse CNS. These human neuron-like cells are an attractive model system for studies of neuronal development, polarity and transplantation.

=> d his

(FILE 'HOME' ENTERED AT 09:52:39 ON 08 JAN 2003)

FILE 'MEDLINE' ENTERED AT 09:52:45 ON 08 JAN 2003

L1 3 S POST-MITOTIC HUMAN NEURON
L2 108 S POST-MITOTIC NEURON
L3 157887 S IMPLANT?
L4 0 S L1 (S) L3
L5 2 S L2 (S) L3
L6 1484089 S TREATMENT
L7 1819680 S TREAT?

L8 68237 S ALZHEIMERS DISEASE OR PARKINSONS DISEASE OR HUNTINGTONS DISEASE
L9 123638 S ALZHEIMER? DISEASE OR PARKINSON? DISEASE OR HUNTINGTON? DISEASE
L10 .229826 S POST-MITOTIC NEURON OR NEURON
L11 344762 S REVIEW
L12 171 S L3 (S) L6 (S) L9
L13 13 S L3 (S) L6 (S) L9 (S) L11
L14 0 S L3 (S) L6 (S) L9 (S) L11 (S) L10
L15 8 S L3 (S) L6 (S) L11 (S) L10

FILE 'PCTFULL, USPATFULL, MEDLINE, BIOSIS, EMBASE, CAPLUS, CONFSCI, SCISEARCH' ENTERED AT 10:17:36 ON 08 JAN 2003

L16 9 S L5
L17 5 DUP REM L16 (4 DUPLICATES REMOVED)

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION
18 50 39 12

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:20:47 ON 08 JAN 2003

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1632rrs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * * * * * Welcome to STN International * * * * * * * * * * *

| NEWS | 1 | Web Page URLs for STN Seminar Schedule - N. America |
|------|----|--|
| NEWS | 2 | Apr 08 "Ask CAS" for self-help around the clock |
| NEWS | 3 | Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area |
| NEWS | 4 | Apr 09 ZDB will be removed from STN |
| NEWS | 5 | Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB |
| NEWS | 6 | Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS |
| NEWS | 7 | Apr 22 BIOSIS Gene Names now available in TOXCENTER |
| NEWS | 8 | Apr 22 Federal Research in Progress (FEDRIP) now available |
| NEWS | 9 | Jun 03 New e-mail delivery for search results now available |
| NEWS | 10 | Jun 10 MEDLINE Reload |
| NEWS | 11 | Jun 10 PCTFULL has been reloaded |
| NEWS | 12 | Jul 02 FOREGE no longer contains STANDARDS file segment |
| NEWS | 13 | Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid |
| NEWS | 14 | Jul 29 Enhanced polymer searching in REGISTRY |
| NEWS | 15 | Jul 30 NETFIRST to be removed from STN |
| NEWS | 16 | Aug 08 CANCERLIT reload |
| NEWS | 17 | Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN |
| NEWS | 18 | Aug 08 NTIS has been reloaded and enhanced |
| NEWS | 19 | Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN |
| NEWS | 20 | Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded |
| NEWS | 21 | Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded |
| NEWS | 22 | Aug 26 Sequence searching in REGISTRY enhanced |
| NEWS | 23 | Sep 03 JAPIO has been reloaded and enhanced |
| NEWS | 24 | Sep 16 Experimental properties added to the REGISTRY file |
| NEWS | 25 | Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS |
| NEWS | 26 | Sep 16 CA Section Thesaurus available in CAPLUS and CA |
| NEWS | 27 | Oct 01 CASREACT Enriched with Reactions from 1907 to 1985 |
| NEWS | 28 | Oct 21 EVENTLINE has been reloaded |
| NEWS | 29 | Oct 24 BEILSTEIN adds new search fields |
| NEWS | 30 | Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN |
| NEWS | 31 | Oct 25 MEDLINE SDI run of October 8, 2002 |
| NEWS | 32 | Nov 18 DKILIT has been renamed APOLLIT |
| NEWS | 33 | Nov 25 More calculated properties added to REGISTRY |
| NEWS | 34 | Dec 02 TIBKAT will be removed from STN |
| NEWS | 35 | Dec 04 CSA files on STN |
| NEWS | 36 | Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date |
| NEWS | 37 | Dec 17 TOXCENTER enhanced with additional content |
| NEWS | 38 | Dec 17 Adis Clinical Trials Insight now available on STN |